Movement Alert｜Hinge Health, Inc. Rises 9.84% in Regular Trading, Q2 Revenue Significantly Beats Expectations and Full-Year Guidance Substantially Raised

Market Focus08-08

On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant upward revision to full-year revenue guidance, further supported by Morgan Stanley raising its price target.

The company reported Q2 revenue of $212.8 million, beating the consensus estimate of $201.5 million by approximately 5.6% and representing a 53% year-over-year increase. Adjusted EPS came in at $0.59, in line with expectations. More notably, Hinge Health raised its full-year revenue guidance to $856 million-$860 million, well above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Morgan Stanley raised its price target from $108 to $117, maintaining an Overweight rating, with the analyst consensus mean target at $100.67.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105791568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-08 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105791568","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hinge Health, Inc. Rises 9.84% in Regular Trading, Q2 Revenue Significantly Beats Expectations and Full-Year Guidance Substantially Raised","media":"Market Focus","content":"<p><p>On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant upward revision to full-year revenue guidance, further supported by Morgan Stanley raising its price target.</p><p>The company reported Q2 revenue of $212.8 million, beating the consensus estimate of $201.5 million by approximately 5.6% and representing a 53% year-over-year increase. Adjusted EPS came in at $0.59, in line with expectations. More notably, Hinge Health raised its full-year revenue guidance to $856 million-$860 million, well above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Morgan Stanley raised its price target from $108 to $117, maintaining an Overweight rating, with the analyst consensus mean target at $100.67.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hinge Health, Inc. Rises 9.84% in Regular Trading, Q2 Revenue Significantly Beats Expectations and Full-Year Guidance Substantially Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hinge Health, Inc. Rises 9.84% in Regular Trading, Q2 Revenue Significantly Beats Expectations and Full-Year Guidance Substantially Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-08 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant upward revision to full-year revenue guidance, further supported by Morgan Stanley raising its price target.</p><p>The company reported Q2 revenue of $212.8 million, beating the consensus estimate of $201.5 million by approximately 5.6% and representing a 53% year-over-year increase. Adjusted EPS came in at $0.59, in line with expectations. More notably, Hinge Health raised its full-year revenue guidance to $856 million-$860 million, well above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Morgan Stanley raised its price target from $108 to $117, maintaining an Overweight rating, with the analyst consensus mean target at $100.67.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HNGE","symbol_name":"Hinge Health, Inc.","start_time":0,"source_url":"","article_id":"1105791568","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105791568","pubTimestamp":1786119336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HNGE":"Hinge Health, Inc."},"translate_title":"走势警报|Hinge Health, Inc. 常规交易上涨 9.84%，第二季度收入大幅超出预期，全年指引大幅上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HNGE":1},"content_text":"On August 8, Hinge Health, Inc. rose 9.84% in regular trading, trading at $87.87/share, with turnover of $92.48 million. The stock continues to rally following strong Q2 results and a significant upward revision to full-year revenue guidance, further supported by Morgan Stanley raising its price target.The company reported Q2 revenue of $212.8 million, beating the consensus estimate of $201.5 million by approximately 5.6% and representing a 53% year-over-year increase. Adjusted EPS came in at $0.59, in line with expectations. More notably, Hinge Health raised its full-year revenue guidance to $856 million-$860 million, well above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Morgan Stanley raised its price target from $108 to $117, maintaining an Overweight rating, with the analyst consensus mean target at $100.67.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105791568","isCrawlerRequest":true}